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ABSTRACT
Synthesis of selenoproteins depends on decoding of
the UGA stop codon as the amino acid selenocys-
teine (Sec). This process requires the presence of
a Sec insertion sequence element (SECIS) in the
3’-untranslated region of selenoprotein mRNAs and
its interaction with the SECIS binding protein 2
(SBP2). In humans, mutations in the SBP2-encoding
gene Sec insertion sequence binding protein 2
(SECISBP2) that alter the amino acid sequence
or cause splicing defects lead to abnormal thyroid
hormone metabolism. Herein, we present the first
in silico and in vivo functional characterization
of alternative splicing of SECISBP2. We report a
complex splicing pattern in the 5’-region of human
SECISBP2, wherein at least eight splice variants
encode five isoforms with varying N-terminal
sequence. One of the isoforms, mtSBP2, contains a
mitochondrial targeting sequence and localizes to
mitochondria. Using a minigene-based in vivo spli-
cing assay we characterized the splicing efficiency
of several alternative transcripts, and show that the
splicing event that creates mtSBP2 can be modu-
lated by antisense oligonucleotides. Moreover, we
show that full-length SBP2 and some alternatively
spliced variants are subject to a coordinated tran-
scriptional and translational regulation in response
to ultraviolet type A irradiation-induced stress.
Overall, our data broadens the functional scope of
a housekeeping protein essential to selenium
metabolism.
INTRODUCTION
Selenocysteine (Sec), the 21st amino acid in the genetic
code, is incorporated into a subset of proteins termed
selenoproteins in response to an in-frame UGA codon
(1). Since the UGA codon most commonly signals trans-
lation termination, its decoding as Sec relies on the pre-
sence of several unique, evolutionary conserved structures
and protein factors. The major cis-acting determinant for
Sec incorporation is the Sec insertion sequence (SECIS)
element, a stem–loop RNA structure located within the
30-untranslated region (UTR) of all eukaryotic selenopro-
tein mRNAs (2,3). This element acts by recruiting the
specialized protein complexes required for the read-
through of UGA and translation of selenoproteins. An
additional RNA structure able to support UGA codon
read-through, named the Sec redeﬁnition element (SRE),
has been recently identiﬁed within the coding region of
selenoprotein N, a few nucleotides downstream of the
UGA codon (4). While the SECIS element is absolutely
required for Sec incorporation, the SRE appears to play
only a ﬁne-tuning role in determining the UGA decoding
eﬃciency for some selenoproteins (5). Synthesis, delivery
and incorporation of Sec into polypeptide chains is sup-
ported by selenocysteyl-tRNA[Ser]Sec(1) and by a set of
specialized proteins [reviewed in (6)], including SECIS
binding protein 2 (SBP2) (7,8), Sec-speciﬁc elongation
factor eEFSec (9,10), ribosomal protein L30 (11),
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the 43 kDa RNA binding protein (SECp43) and Sec
synthase (12). Although much progress has been made
in delineating individual components required for seleno-
protein synthesis, the overall mechanism that directs this
process is not fully understood.
SBP2 is one of the most studied selenoprotein synthesis
factors, initially shown to be required for this process in
reticulocyte lysates and in vitro assays (8,13). Consistent
with this, we have shown that SBP2 depletion in human
cells leads to decreased selenoprotein synthesis (14).
Hereafter, we refer to SBP2 as protein, whereas Sec inser-
tion sequence binding protein 2 (SECISBP2) in italicized
letters refers to gene or transcript. The ﬁrst in vivo evidence
showing that SBP2 is epistatic to selenoprotein synthesis
was recently provided in a study that identiﬁed mutations
in SECISBP2 in families presenting with clinical evidence
of abnormal thyroid hormone metabolism (15). This
was manifested through lack of functional selenoenzyme
deiodinase 2 (DIO2) and dramatically reduced levels of
selenoprotein P in aﬀected individuals (15). Detailed bio-
chemical and functional characterization of SBP2 has
been carried out; however, its regulation at the gene and
transcript level requires further studies.
Alternative splicing represents a functionally important
and a major regulatory pathway of gene expression and
ultimately protein function. Recent genomic studies have
indicated that at least 60% of mammalian genes are sub-
jected to alternative splicing (16), providing a signiﬁcant
contribution to protein diversity beyond that encoded in
the genome sequence. Most alternative splicing events
aﬀect the coding sequence and it is believed that half of
these alter the reading frame (17), and a third lead to non-
sense mediated decay (NMD) of the RNA product (18).
Defects in alternative splicing and generation of aberrant
ratios of mRNA transcripts from a single gene are now
also recognized as major contributors to human disease
and it is estimated that at least 15% of the mutations that
cause hereditary disease aﬀect pre-mRNA splicing (19).
Splicing defects have also been associated with cancers
and a genome wide analysis of human expressed sequence
tags (ESTs) found strong evidence for cancer speciﬁc
splice variants in 316 human genes (20–24). To date, this
level of regulation has not been explored for any of the
factors involved in Sec incorporation, including SBP2.
SBP2 is the only protein of the Sec incorporation
machinery so far linked to a clinical condition (15). Inter-
estingly, one of the mutations identiﬁed in patients
alters the splicing of SECISBP2 by creating an alter-
native donor splice site, which produces a transcript
with a 26 bp intron retention. This event alters the reading
frame upstream of the SBP2 RNA-binding domain, giving
rise to a truncated, non-functional protein. The regula-
tion of SBP2 expression by alternative splicing thus
appears to have signiﬁcant implications for its function.
Prompted by these ﬁndings, we herein carried out in silico,
as well as functional analysis of alternative splicing of
SECISBP2. We now provide evidence for a complex
alternative splicing pattern in the 50-region of human
SECISBP2 that give rise to eight spliced variants gener-
ated through diﬀerent exon combinations. All alternative
splicing events are conﬁned within the region of SBP2 that
is dispensable for Sec incorporation in vitro, but may be
involved in regulation of selenoprotein synthesis in vivo.
Interestingly, one of the alternatively spliced isoforms con-
tains a mitochondrial targeting sequence (MTS). We
designated this transcript as mitochondrial Sec insertion
sequence binding protein 2 (mtSECISBP2). First, using a
minigene-based in vivo splicing assay we delineated the
splicing events within the 50-region of SECISBP2 and
showed that splicing of mtSECISBP2 can be modulated
by antisense oligonucleotides (ASOs). We furthermore
demonstrated that the protein encoded by mtSECISBP2
does indeed localize to mitochondria and that transcrip-
tion and translation of SBP2 is regulated in a coordinated
manner in response to stress.
MATERIALS AND METHODS
In silico identification of alternatively spliced
forms of SBP2
The previously characterized human full-length
SECISBP2 gene (GeneBank ID: NM_024077) was used
to search against both the EST and the non-redundant
(NR) nucleotide databases to identify alternative forms
of human SECISBP2 gene. Sequence analyses were per-
formed using BLAST programs (available at http://
www.ncbi.nlm.nih.gov/BLAST/) with default parameters.
Tissue- and cell-type information of various ESTs was
also retrieved from EST database. Identiﬁed sequences
that were homologous to SECISBP2 were then mapped
to human genomic sequences to analyze genomic struc-
tures of detected alternative forms. Cellular localizations
of proteins were predicted by PSORT II (http://psort.
ims.u-tokyo.ac.jp/form2.html).
Cell culture and treatments
The cell lines human embryonic kidney 293T, human
cervical carcinoma C33A, human cervical carcinoma
HeLa and normal foreskin ﬁbroblast (NFF) cells, were
maintained in RPMI 1640 medium supplemented with
10% fetal calf serum (Gibco-BRL, Gaithersburg, MD,
USA) and 1% penicillin/streptomycin, in a humidiﬁed
atmosphere containing 5% CO2. For Ultraviolet A
(UVA) treatments, media was removed and kept at 378C,
and phosphate buﬀered saline (PBS) was added. Cells
were subjected to a dose of 50 kJ/m2 of UVA irradiation.
Control cells were maintained in PBS at room temperature,
in the dark, for the duration of treatment. Following
irradiation, the PBS was replaced with the media
and cells were allowed to recover for the time indicated.
Generation of minigenes
SECISBP2 minigene splicing cassette was generated
by amplifying genomic sequences starting from exon 1
through exon 4 of the SECISBP2 gene with high-ﬁdelity
Pfx polymerase (Invitrogen, Carlsbad, CA, USA) and
genomic DNA (Clontech Laboratories, Inc. Palo Alto,
CA, USA). Appropriate primers were used to reduce the
size of intron 2 from 5.6 kb to 356 nt that include 184
residues of the 50-end of intron 2 and 172 residues of the
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30-end of intron 2. An 2.3 kb ampliﬁed fragment from
genomic SECISBP2 containing entire exon 1, entire
intron 1, entire exon 2, partial intron 2 (only 356 nt),
entire exon 3, entire intron 3 and entire exon 4 was
cloned into pCI vector (Promega) between Xho I and
Not I site. Subsequently, genomic sequences from the
pCI vector were subcloned into a SBP2-GFP plasmid
described previously (14). Here, appropriate primers
were used to replace exon 1 through exon 4 of SBP2
cDNA sequence with 2.3 kb genomic sequence described
above (Figure 2A). The complete SBP2 minigene sequence
is provided as supplementary data. Mutations were intro-
duced using the Quick-Change site directed mutagenesis
kit (Stratagene) as per manufacturer’s instructions.
Antisense oligonucleotides
ASOs were synthesized by Dharmacon, Inc. The
sequences of the oligonucleotides used are as follows:
mG()mA()mU()mC()mG()mA()mU()mC()mG()
mA()mU()mC()mG()mA()mU()mC()mG()mA()
mU()mC()mG()mA for the control ASO (GATC) and
mCmUmGmCmCmUmAmAmGmUmAmA
mAmAmAmGmUmGmUmAmAmAmC for the
SBP2 speciﬁc ASO spanning the intron 2-exon 3a bound-
ary (In2E3a). In these sequences, the letter m represents an
O-methyl modiﬁcation at the second position of a sugar
residue and an asterisk represents a phosphorothioate
modiﬁcation of the backbone.
Transfections and in vivo splicing assays
All reagents were used according to the manufacturer’s
recommendations. Transient transfections of cells with
plasmid DNA or antisense oligonucleotides were per-
formed with Lipofectamine 2000 (Invitrogen). Cells were
plated into 6-well plates 24 h prior to transfection so
that their density on the day of transfection was
70%. 2.0 mg of plasmid DNA was used per well. For
co-transfection experiments, cells were transfected with
1.0mg of plasmid DNA and 100 nM of ASO per well.
Total RNA was isolated 24 h after transfection with
Trizol reagent (Invitrogen). To generate cDNA, reverse
transcription was carried out with a SuperScript II reaction
kit (Invitrogen) using oligo(dT) primer. Generally, 1.0 mg
of total RNA was used per 20 ml of reaction mixture.
Minigene-speciﬁc spliced products were subsequently
ampliﬁed with forward primer annealing in the vector
sequence (P1GFP) 50-GCTAGCGCATCCGGACTCA
GAT-30, and the reverse SBP2-speciﬁc primer annealing
in exon3b 50-CTTAAACAGAGCTTTCATTTCTTGTG
G-30 using Taq polymerase (Invitrogen). Analysis and
quantiﬁcations of spliced products were performed with
an FPL-5000 Image Reader and ImageGauge software
(Fuji Photo Film Inc.) Results were conﬁrmed by three
independent experiments.
Expression of endogenous SECISBP2 transcripts
For analysis of endogenous full-length SECISBP2 and
mtSECISBP2, C33A, HeLa and 239T cells were trans-
fected with 100 nM ASOs per well of a 6-well dish.
Total RNA was isolated 24 h after transfection with the
RNeasy Mini Kit (Qiagen). Reverse transcription was car-
ried out with oligo (dT) primers and SuperScript II
(Invitrogen) as described above. Full-length SECISBP2
and mtSECISBP2 transcripts were subsequently ampliﬁed
by real-time RT-PCR with transcript-speciﬁc forward
primers 50-TCCTTATACCCTTGACTCCACA-30 for
full-length SECISBP2 and 50-CCAGTGACAGAAATG
TTTACTCAG-30 for mtSECISBP2, and the same reverse
primer 50-TCCTGTCTGTTCGCTTATGG-30. Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) was used
as an internal standard (Fwd 50-CTGCACACCAAC
TGCTTAG-30; Rev 50-GTCTTCTGGGTGGCAGTG
AT-30). Real-time RT-PCR was performed using Platinum
SYBR Green qPCR SuperMix-UDG (Invitrogen) in a
Rotor-Gene 6000 (Corbett Life Science) according to the
instructions provided with the kit. Cycling conditions were
used as suggested in the SYBR Green kit instructions.
Results were analyzed using relative quantiﬁcation soft-
ware (Corbett Life Science).
Cell lysis and western blotting
Cells were lyzed in universal immunoprecipitation buﬀer
(UIP) as described previously (14). Proteins were sepa-
rated on 4–12% gradient gels (Invitrogen) unless other-
wise stated. Western blotting was performed using the
following antibodies: anti-SBP2 and anti-HSP70 antibo-
dies raised in house as described previously (14), anti-actin
(Sigma), anti-GFP (Molecular Probes, Invitrogen) and
anti-SBP2 antibodies (EC1) (Everest Biotech, Oxford-
shire, UK). Except for Figure 4B, images were acquired
using an LAS-3000 luminescent image analyzer (Fujiﬁlm
Life Science, Stanford, CT, USA). The western blot in
Figure 4B was developed using traditional X-ray ﬁlm.
Fluorescence microscopy
Cells, untransfected or transfected with GFP-tagged pro-
teins, were washed in PBS twice and ﬁxed with 4% paraf-
ormaldehyde in PBS for 30min at room temperature.
40,60-Diamidino-2-phenylindole (DAPI) was used to stain
the nuclei and MitoTracker CMXRos (Molecular Probes,
Invitrogen) (50 nM) was used to stain mitochondria.
For immunoﬂuorescence, coverslips were blocked in 3%
horse serum in PBS, incubated with anti-SBP2 antibody
(EC1) at 1 : 250 dilution, followed by incubation with an
Alexa ﬂuor 488 dye-conjugated secondary antibody
(Molecular Probes, Invitrogen). Colocalization of SBP2
with mitochondria was detected using a double immuno-
ﬂuorescent procedure. Coverslips were mounted with
ProLong Gold (Molecular Probes, Invitrogen). Images
were acquired in 20 z-sections by using a state-of-the art
DeltaVision PD system microscope (Applied Precision,
Washington, USA) with a 60 or 100 objective.
Images were subsequently deconvolved with 10 cycles of
the DeltaVision PD software.
RESULTS
Human SBP2 is alternatively spliced
In humans, the SECISBP2 gene spans a 43 kb region
on chromosome 9q22.1 and consists of 17 exons.
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Following reverse transcription PCR (RT-PCR) of the
50-end of SECISBP2 using mRNA isolated from 293T
cells, we observed a second PCR product, shorter than
the full-length transcript (data not shown). Sequence
analysis of this band identiﬁed two alternatively spliced
SECISBP2 variants: one lacking exon 2, and the second
lacking part of exon 3, further designated exon 3a. To
further examine whether additional SECISBP2 splice
variants were present in humans, we searched EST and
NR databases using known full-length SECISBP2
sequences and mapped and quantiﬁed the identiﬁed
cDNAs onto the genomic sequence. This search con-
ﬁrmed that full-length SECISBP2 is indeed the most
abundant transcript, currently represented by 120
ESTs and 5 complete mRNAs, and led to the identiﬁca-
tion of seven alternatively spliced SECISBP2 variants
arising through diﬀerent exon combinations. These var-
iants are as listed in Table 1 along with their proposed
nomenclature. A schematic representation of the genomic
organization of human SECISBP2 is shown in
Figure 1A, and the spliced variants for which suﬃcient
sequence was available to determine their complete
50-exon combination are presented in Figure 1B. The
three functional domains of SBP2: the RNA binding
domain, the Sec insertion domain and the ribosome
interacting domain, are located within the C-terminal
part of the protein (8,25), which corresponds to exons
12–16. Interestingly, all alternative splicing events occur
upstream of exon 11, within the region dispensable for
Sec insertion in vitro.
Sequence analysis of exon/intron boundaries showed
that nearly all splice sites within the 50-region of
SECISBP2 conform to consensus sequences (AAG|GU
or CAG|GU at the 50-exon/intron boundary and
CAG|G at the 30-end) (26) with only a few deviations
(Table 2). The majority of exons have one donor and
one acceptor splice site; however, exons 3 and 7 have
multiple acceptor sites, denoted as a, b, c or d. A very
complex splicing pattern was noted between exons 6 and
7, with four possible splicing combinations. The most
common acceptor site was the 7a site. The 6–7b splice
variant appeared to be rare, however, an encoding
mRNA derived from brain tissue (Table 1) was present
in the EST database. The variants 6–7c and 6–7d were
covered by several ESTs.
All SECISBP2 transcripts for which suﬃcient
50-sequence information was available appear to begin
with exon 1. This suggests the usage of a common promo-
ter, located upstream of exon 1. As mentioned above, the
overwhelming majority of SECISBP2 transcripts include
all exons. However, the alternatively spliced SECISBP2
variants seem to be expressed in normal as well as in
cancer-derived tissues (Table 1). The best represented
alternatively spliced transcript lacked exon 3a as evi-
denced by 24 ESTs from normal and cancer-derived tis-
sues and cell lines, and was also covered by three complete
mRNAs (Table 1). Despite the presence of a large number
of ESTs covering the 50-region of SECISBP2 sequence, no
alternative splicing events were detected downstream of
exon 10.
Alternative splicing of SECISBP2 creates several
open reading frames
We next examined the nucleotide sequences of the various
transcripts for their potential to encode complete open
reading frames (ORFs), and found that ﬁve SBP2 iso-
forms initiating from ﬁve diﬀerent ATG start sites can
be encoded (Figure 1C). As previously shown, the full-
length SBP2 is translated using the ﬁrst ATG codon in
exon 1. This main ORF is however abrogated for some
of the variants as premature termination codons (PTCs)
are generated, suggesting a possibility of the use of alter-
native ATG start sites. As indicated in Figure 1B, these
potential alternative translation initiation sites (referred
by amino acid numbering in full-length SBP2) are methio-
nine (Met) 69 within exon 3a for SBP2_2, and Met 233
within exon 5 for SBP2_3 and they are in the same frame
as full-length SBP2. However, for the mtSECISBP2
and SECISBP2E6 transcripts, the ﬁrst ATG codon down-
stream of the PTC is created in a diﬀerent frame in
exon 2 (Met 33) and in exon 6 (Met 283) respectively
(Figure 1B). These reading frames create a short
N-terminal amino acid composition diﬀerent to full-
length SBP2 (i.e., 27 aa for mtSBP2 MVRVLRSMCLP
QLCSHILSVCSGTTSDR, and 11 aa for SBP2E6 MP
LPILLHVQE), however, these reconnect with the full-
length SBP2 reading frame at the next splice site.
Interestingly, motif analysis using the PSORTII program
predicted the existence of a classical MTS within the exon
3a-deleted variant (Figure 1C), and this form is further
designated as mitochondrial SBP2, mtSBP2. The alternate
reading frame for SBP2E6 did not seem to encode any
targeting signals or motifs diﬀerent to full-length SBP2.
The complex splicing pattern between exon 6 and 7 was
interesting as all splicing variations lead to changes in the
amino acid composition of the encoded proteins. The spli-
cing from exon 6–7c and 6–7d lead to deletion of a stretch
of 38 or 39 amino acids (aa 294–331 or aa 294–332) from
exon 7 (294ELSWTPMGYVVRQTLSTELSAAPKNVTS
MINLKTIASS331), however, the reading frame starting
in exon 1 is maintained throughout both isoforms. The
ESTs covering the SECISBP2_D9 transcript did not
have suﬃcient sequence upstream of the splicing event in
order to determine its translation initiation sites; however,
ORF prediction indicated that the reading frame in exon 1
can be maintained despite exon 9 skipping.
Evolutionary aspects of splicing events within SBP2
We next investigated the extent of alternative splicing
events in SBP2 in other species. We thus analyzed the
distribution of SECISBP2 homologs, the conservation
of splicing events and evolution of the SECISBP2 gene
in genomic and EST databases. As recently established,
selenoprotein genes are widely distributed among eukar-
yotes including all vertebrates and most arthropods,
nematodes, protozoa and lower plants (27–29). Selenopro-
teins were lost in fungi, land plants, some insects and most
eukaryotic parasites. We found that SECISBP2 homologs
are present in all selenoprotein-containing genomes, and
absent in EST and genomic databases of organisms lack-
ing Sec utilization, suggesting that SECISBP2 co-evolved
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SBP2
SBP2_D2
MTSBP2
Start
codon
Met 1
Met 69
Met 33
MW
(kDa)
95.8
86.0
85.9 (79.4*)
Indicates the location of the ATG codon used for translation initiation
*   Indicates molecular weight after cleavage of mitochondrial targeting sequence
SBP2E6 Met 283
SBP2_D3 Met 233 69.2
Isoform
1 ATG GCG TCG GAG GGG CCG CGG GAG CCC GAA AGC GAG| GGC ATC AAG TTA TCA
M  A  S  E  G  P  R  E  P  E  S  E  G  I  K  L  S     Frame 1
W  R  R  R  G  R  G  S  P  K  A  R  A  S  S  Y  Q    Frame 2
G  V  G  G  A  A  G  A  R  K  R  G  H  Q  V  I  S   Frame 3
GCA GAT GTC AAA CCA TTT GTC CCC AGA TTT GCC GGG CTC AAT GTG GCA TGG
A  D  V  K  P  F  V  P  R  F  A  G  L  N  V  A  W     Frame 1
Q  M  S  N  H  L  S  P  D  L  P  G  S  M  W  H  G    Frame 2
R  C  Q  T  I  C  P  Q  I  C  R  A  Q  C  G  M  V Frame 3
TTA GAG TCC TCA GAA GCA TGT GTC TTC CCC AGC TCT GCA GCC ACA
L  E  S  S  E  A  C  V  F  P  S  S  A  A  T…… Frame 1
*  S  P  Q  K  H  V  S  S  P  A  L  Q  P  H…… Frame 2
R  V  L  R  S M  C  L P  Q  L C  S H  I…… Frame 3
SBP2
mtSBP2
SBP2
SBP2
mtSBP2
mtSBP2
exon 1 exon 2
A
C
1 2 3 4 5 6 7 8 9 10 11
Human SECISBP2 gene organization
116 146 250 142 227 78 209 123 90 133 167 136 154 221 155 193 922Size
(bp)
Exons:
1 2 3 4 5 6 7a b a b c
B
RNA binding and Sec
incorporation domains
62.4
12 13 14 15 16 17
Figure 1. Schematic representation of human SECISBP2 transcript variants. (A) Genomic organisation of SECISBP2 showing the 17 exons and
their sizes in base pairs (bp). Locations of the functional domains are indicated. (B) Alternatively spliced SECISBP2 transcript variants generated
through diﬀerent exon combinations are shown schematically. Arrowheads indicate translation start sites. Designation for the encoded protein
isoforms, the corresponding Met start codon number [based on numbering in the full-length human SBP2 sequence (NP_076982)] and predicted
molecular weights (MW) of isoforms are indicated to the right of each transcript. (C) An alternative reading frame used for translation of the
mitochondrial SBP2 isoform (mtSBP2) initiates in exon 2 (indicated by arrow). The encoded mitochondrial targeting sequence is underlined.
Table 2. Splice site boundaries of SECISBP2 transcript variants
Donor exon
(nt) 
Acceptor exon
(nt) 
Intro
size(kb)
EXON/intron/EXON 
(splice site consensus: …AG|guragu…(y)10-15nyag|G…)
1 (116) 2 (146) 1.04 …AGCGAG|guaagg…ucauauuuuuccucag|GGCAUC… 
1 (116) *3a (121) 6.81 …AGCGAG|guaagg…uuuacacuuuuuacuuag|GCAGAA… 
2 (146) *3a (121) 5.63 …GACAGA|guaugu…uuuacacuuuuuacuuag|GCAGAA… 
2 (146) *3b (129) 5.63 …GACAGA|guaugu…uacccuugacuccacacag|AAUGUU… 
2 (146) 4 (142) 5.63 …GACAGA|guaugu…uuuuuaaucuuuccugcag|AAGAAA 
3 (250) 4 (142) 0.20 …UUUAAG|gugagu…uuuuuaaucuuuccugcag|AAGAAA… 
4 (142) 5 (227) 2.67 …AAUCAG|guaaaa…uuuaauuuuguaauuacag|AUGGUU… 
5 (227) 6 (78) 4.02 …UCAAAG|gugagg…uaauguguuugcuuuuuag|GGUGAA… 
6 (79) *7a (209) 1.53 …CAAGAG|guaaaa…uuuugguuaucuuugagcag|AGUUAU… 
6 (79) *7b (171) 1.53 …CAAGAG|guuaucuu…guuauguuguucgacag|ACAUUA… 
6 (79) *7c (95) 1.53 …CAAGAG|guaaaa…accauuucaucag|CAGAUG…
6 (79) *7d (92) 1.53 …CAAGAG|guaaaa…ccauugcuucagcag|AUCCU… 
8 (123) 10 (132) 2.76 …AUUGAA|guaguac…uuuugaacuuucag|GAUAAU… 
The donor and acceptor exons are listed with their sizes in nucleotides (nt) in brackets. Intron sizes are given in kilobases (kb). Boundaries of splice
sites was identiﬁed from the genomic DNA sequence (http://genome.ucsc.edu) and compared to the consensus of splice site motifs (16). Consensus
nucleotides at the 50 and 30 splice sites are indicated in bold letters and splice sites are indicated with a vertical line. The polypyrimidine stretch is
shown in italics.
Exons with alternative donor or acceptor sites.
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with the eukaryotic Sec-decoding trait. Several alterna-
tively spliced transcripts were found in EST and genomic
databases of diﬀerent organisms, some of which were
identical to human SECISBP2. Because the mtSBP2 is
the most common isoform after full-length SBP2
in humans, we were particularly interested in its evolution-
ary conservation and existence in other species. Interest-
ingly, sequence comparison between exon 2 of human
SECISBP2 and other homologs revealed that the ATG
codon is conserved in chicken, sheep, pig, cow and
monkey but not in mouse, rat and dog where it is present
as GTG or CTG, which are possible weak translation
initiation codons. However, we did not detect ESTs repre-
senting mtSECISBP2 in other organisms except for a dis-
tant homolog containing a strong predicted MTS (but low
sequence similarity to human MTS) in chicken. It thus
appears that the predicted mtSBP2 isoform may be speci-
ﬁc to humans.
Characterization of SBP2 splicing in vivo and modulation
with antisense oligonucleotides
The identiﬁcation of alternative splicing within the
50-region of human SECISBP2 prompted us to further
characterize and quantify the occurrence of these
events in vivo. We were particularly interested in the
mtSECISBP2 variant since it appeared to be the best
represented transcript after the full-length transcript. To
gain a better insight into the expression pattern of the
two transcripts, we ﬁrst quantiﬁed their relative expression
levels in a cDNA panel from various human tissues by real-
time RT-PCR using isoform-speciﬁc primers spanning the
exon 2–3a boundary for SECISBP2, and the exon 2–3b
boundary for mtSECISBP2. As shown in Figure 2A,
SECISBP2 and mtSECISBP2 were expressed in all tissues
tested, with the highest expression levels for both tran-
scripts in testis. The ratio between the SECISBP2 and
mtSECISBP2 was on average 4.4 : 1 in most tissues,
which is consistent with the bioinformatics data presented
in Table 1. However, colon, thymus and leucocytes had
a 2 : 1 ratio, indicating that mtSECISBP2 is most abun-
dantly expressed relative to SECISBP2 in these tissues. We
also conﬁrmed the expression ofmtSECISBP2 variant in a
number of normal and cancer-derived cell lines including
ones used in this study (data not shown).
As a second approach to characterize and potentially
modulate SECISBP2 splicing in vivo, we generated a
SECISBP2 minigene construct (WT minigene), schemati-
cally presented in Figure 2B. We also generated two
mutant minigene constructs: one harbouring a point
mutation at the exon 3a 30 splice site 359AG>AA
(named Ex3AG>AAT) which should abrogate the spli-
cing at this site and hence deplete the production of
mtSECISBP2; and a second construct harbouring a
point mutation (99ATG>CTG) to abrogate mtSBP2
start codon in exon 2 (named Ex2ATG>CTG). The mini-
genes were transfected into C33A cells and products were
analyzed by RT-PCR using primers speciﬁc to the
minigene-derived transcripts as indicated in Figure 2B.
The a-32P-dCTP labeled products were separated by
native PAGE and veriﬁed by sequencing. As shown in
Figure 2C, lane 1, full-length SECISBP2 was the predo-
minant transcript expressed from the WT minigene, fol-
lowed by mtSECISBP2 and SECISBP2_2. These results
conﬁrmed that mtSECISBP2 may indeed be the second
most abundant SECISBP2 transcript. Notably, the
Ex3AG>AA mutation indeed abrogated the exon 3a 30
splice site responsible for the skipping of exon 3a, which
is clearly evident by the absence of the mtSBP2 encoding
transcript (Figure 2C, lane 2). This observation also con-
clusively conﬁrmed the existence of an alternative acceptor
site within exon 3, and shows that this site is required for
production of the mtSECISBP2 transcript. As expected,
the ATG mutant minigene showed no diﬀerence in spli-
cing compared to the WT minigene (Figure 2C, lane 3).
ASO with a 20-O-methyl modiﬁed ribonucleotide with
phosphorothioate backbone have been used to manipulate
pre-mRNA splicing in the spinal muscular atrophy gene,
SMN2 (30). This backbone modiﬁcation imparts a very
high aﬃnity for targeted mRNA, resistance to both exo-
and endonucleases and does not support cleavage of
hybridized mRNA by RNAse H (31). We employed this
technology to test whether splicing of the mtSECISBP2
can be enhanced using a 23-mer ASO complementary to
the last 19 nt of intron 2 and the ﬁrst four nucleotides of
exon 3a (named In2E3a). This was expected to promote
exon 3a skipping and thus block splicing of the full-length
transcript and enhance the production of the mtSBP2-
encoding transcript. An unrelated ASO was used as con-
trol. Resulting PCR products from cells co-transfected
with the In2E3a, or control ASO, and the WT minigene
are shown in Figure 2C, lanes 4 and 5. Notably, the
In2E3a ASO eﬃciently blocked splicing at the exon 3a
site, thus, promoting exon 3a skipping as shown by a
dramatic reduction in full-length transcript levels and a
corresponding increase in mtSECISBP2 transcript (lane 4),
while the control ASO had no eﬀect on the splicing
pattern (lane 5 compared to lane 1). Similar results were
obtained in HeLa cells (data not shown). The In2E3a ASO
was also eﬃcient in altering the splicing of the endogenous
SECISBP2 transcript in several cell lines, as measured
by real-time RT-PCR with isoform-speciﬁc primers.
Generally, a 2- to 4-fold increase in exon 3a skipping
with a corresponding 50–60% decrease in exon 3a inclu-
sion was obtained in cell lines including C33A, HeLa and
untransformed human ﬁbroblast cells (NFF). Results
from NFF cells are shown in ﬁgure 2D. Taken together,
these ﬁndings demonstrated that the In2E3a ASO can
be used as an eﬃcient tool to promote SBP2 exon 3a
skipping in vivo, and to generate predominantly the
mtSBP2-encoding transcript from SECISBP2 gene.
Several SBP2 isoforms are expressed from the minigene
We next investigated the translation pattern of the alter-
natively spliced SBP2 isoforms using the minigene con-
structs. These were transiently transfected in several cell
lines including 293T, C33A and HeLa, and the expressed
proteins were analyzed by western blotting. Blots were
probed with anti-GFP antibodies (which is tagged at the
C-terminus of SBP2), and with anti-SBP2 antibodies
raised against a central region of SBP2 (exon 6–8) to
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ensure that the proteins detected are products that initiate
at diﬀerent ATG codons within the N-terminal region of
SBP2 rather than degradation products. A representative
example of the minigenes’ expression pattern in 293T cells
is shown Figure 3A. Consistent with the data obtained
from the splicing assay, full-length SBP2 initiating from
the ATG in exon 1, was by far the highest expressed pro-
tein from the WT and Ex2ATG>CTG minigenes
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Figure 2. SECISBP2 transcript expression and minigene-based in vivo splicing assay. (A) Relative expression levels of full-length and mitochondrial
SBP2 transcripts in a cDNA panel of human tissues was analyzed by real-time PCR using transcript speciﬁc primers. Data was analyzed using the
deltaCT method. (B) Schematic representation of the SECISBP2 minigene indicating exon/intron composition, location of primers used to amplify
the minigene-expressed products, annealing site for antisense oligonucleotides (In2E3a ASO) and location of mutations introduced. (C) In vivo
splicing pattern of SECISBP2 minigene constructs. RT-PCR of a-32P-dCTP labeled products were ampliﬁed from C33A cells transfected with wild-
type (WT), exon 2 ATG>CTG mutant (Ex2ATG>CTG) and exon 3 AG>AA mutant (Ex3AG>AA) minigenes. The exon combination as veriﬁed
by sequencing is indicated on the left (products indicated by  are predicted only). Mutation at the exon 3a acceptor site AG>AA abolishes splicing
between exon 2 and exon 3b as shown by the absence of exon 2–3b spliced product (lane 2). In2E3a ASO treatment almost completely abrogates
exon 2–3a splicing and thus full-length SECISBP2 transcript and dramatically increases exon 2–3b splicing and mtSECISBP2 transcript levels (lane
4). Percentage of exon 3a skipping was calculated from the total value of exon 3a-included and exon 3a-skipped products. (D) Normal human
ﬁbroblast cells were treated with In2E3a ASO and levels of SECISBP2 and mtSECISBP2 were measured by real-time RT-PCR. In2E3a-treated cells
show a 4-fold increase in mtSECISBP2 and 50% decrease in the full-length SECISBP2 transcript.
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(Figure 3A lanes 1 and 2), however, the presence of multi-
ple bands detected by both antibodies suggested that pro-
teins initiating from other ATG start codons are
expressed. Due to the small diﬀerences in their size
(85.9 kDa, 86 kDa, 80 kDa) some of them could not be
resolved and identiﬁed easily. However, the nucleotide
deletion (T367) in exon 3b of the Ex3AG >AAT mini-
gene which abrogates the ORFs starting at ATG codons
in exons 1, 2 or 3a by creating PTCs, enabled us to identify
two of the additional bands as the SBP2 isoforms initiat-
ing in exon 3b from Met 139 and in exon 5 from Met
233 (Figure 3A lane 4). Thus, using the minigene-based
in vivo splicing assay we have been able to convincingly
show that alternative splicing of SECISBP2 may have a
functional relevance as multiple SBP2 isoforms initiating
from diﬀerent ATG start codons and containing diﬀerent
N-termini amino acid composition are being expressed.
Intriguingly, we could not detect a decrease in a band
representing the mtSBP2 protein expressed from the
Ex2ATG>CTG mutant construct (Figure 3A lane 2).
On the contrary, a small increase in expression of
the band below the full-length SBP2 was consistently
seen (Figure 3A lane 2). According to molecular
weight prediction, this band could represent a protein
initiating from ATG codons in exon 3a or exon 3b. We
speculate that the increased expression of this band in the
Ex2ATG>CTG mutant could be the consequence of lack
of translation initiation in exon 2 due to abrogation of the
ATG codon with a consequent promotion of translation
from downstream ATG codons. Although we could not
detect the mtSBP2 isoform expressed from the minigene
by western blotting, its expression levels could be below
the detection limit, but still responsible for regulating
the expression of other downstream ATG-initiating iso-
forms (Figure 3A lane 1 compared to lane 2). However,
this possibility remains to be investigated. We also
noted that translation of the SBP2E3b isoform from the
Ex3AG>AAT minigene did not increase signiﬁcantly
when a point mutation that abrogates the full-length
SBP2 reading frame is introduced (Figure 3A lane 4).
This suggests that the ATG codon context in exon 3b is
rather weak, or that expression of this isoform is strictly
regulated. The overall SBP2 splicing pattern was similar in
other cell lines tested despite variations in transfection
eﬃciency (data not shown).
We showed above (Figure 2B) that the In2E3a ASO is
extremely eﬃcient at increasing the levels of the
mtSECISBP2 transcript both oﬀ the minigene and endo-
genously. We therefore tested if co-transfecting the WT
minigene with the In2E3A ASO could induce the expres-
sion of the mtSBP2 protein. As shown Figure 3B, a band
that corresponds to the predicted size of mtSBP2-GFP
was indeed apparent in In2E3a ASO co-transfected cells,
but not in control ASO transfected cells, demonstrating
that this isoform can be translated in vivo, albeit very
ineﬃciently. Although the In2E3a ASO proved eﬃcient
at inducing splicing of endogenous mtSECISBP2 tran-
script, we were unable to detect the endogenous mtSBP2
protein following In2E3a ASO transfection, despite exten-
sive attempts in several cell lines. Overall, these results
showed that full-length SECISBP2 is the most abundant
and preferentially translated SBP2-encoding transcript.
However, the alternatively spliced transcripts generated
are also translated into protein, albeit far less eﬃciently.
The mtSBP2 isoform localizes to mitochondria
One of the main aims of the minigene splicing assay was
to analyze the expression and localization of the protein
encoded by the most common alternate SECISBP2
transcript-mtSBP2. Although the assay convincingly
showed expression of the mtSECISBP2 transcript, it
proved less amenable at analyzing the protein expression.
Thus, in order to determine if the predicted mtSBP2
does indeed localize to mitochondria, we expressed the
mtSBP2-encoding cDNA (commencing at the ATG
codon in exon 2) fused N-terminal to GFP (mtSBP2-
GFP) in C33A cells, and analyzed its subcellular localiza-
tion by co-staining with the mitochondrial marker
MitoTracker Red CMX-Ros. The full-length FLSBP2-
GFP construct and a construct lacking the putative
MTS encoded by the alternate reading frame in exon 2
(SBP2_2-GFP) were used for comparison. Localization
of the proteins was visualized using a Z-scanning
FLSBP2-GFP 150
120
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WB: GFPWB: SBP2
WT minigene
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−
−
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Figure 3. Minigene-based expression of SBP2 isoforms. (A) The mini-
genes (described in the legend to Figure 2) were transfected into 293T
cells and the proteins expressed were separated on 4–12% gradient gels
and analyzed by western blotting with anti-GFP and anti-SBP2 antibo-
dies. Western blots with the two antibodies show similar staining pattern
and thus conﬁrm the expression of several SBP2 isoforms initiating from
alternative ATG codons. E3aSBP2-GFP, E3bSBP2-GFP and E5SBP2-
GFP refer to isoforms initiating at ATG codons in exons 3a, 3b and 5
respectively. (B)Western blots of cells co-transfected with wild-type (WT)
minigene and the In2E3a antisense oligonucleotides that promotes spli-
cing of the mtSECISBP2 transcript show translation of the mtSBP2GFP
isoform. Actin was used as a control for protein loading.
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microscope followed by image deconvolution. Interest-
ingly, mtSBP2-GFP expressing cells exhibited distinct
cytoplasmic ﬂuorescence, which overlapped signiﬁcantly
with the MitoTracker staining as indicated by the intense
yellow staining in Figure 4A (Pearson coeﬃcient 0.879).
FLSBP2-GFP protein displayed a strong peri-nuclear
punctate staining, however, this ﬂuorescence did not over-
lap signiﬁcantly with the MitoTracker staining (Figure 4A
bottom panels, Pearson coeﬃcient 0.264). Most likely,
this pattern represents a ribosomal/endoplasmic reticulum
(ER) staining which is the believed functional localization
of SBP2 (14,32). Similar to FLSBP2-GFP, SBP2_2-GFP
localized throughout the cytoplasm and showed marginal
co-localization with MitoTracker (data not shown). This
data established that the MTS encoded by the alternative
reading frame in exon 2 is functional, and required for
targeting the mtSBP2-GFP protein to the mitochondria.
It should be noted that only 10% of cells transfected
with the mtSBP2-GFP plasmid displayed strong mito-
chondrial localization as shown in Figure 4A, and some
of the transfected cells also displayed a diﬀuse cytoplasmic
ﬂuorescence that did not co-localize with the MitoTracker
staining (data not shown). Indeed, western blot of
mtSBP2-GFP transfected cells showed the presence of
additional proteins initiating in exon 3b and exon 5
(Figure 4B, lane 4), which explained the cytoplasmic
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Figure 4. Localization of over-expressed mtSBP2-GFP and endogenous mtSBP2 isoform at the mitochondria. (A) The localization of GFP-tagged
full-length (FLSBP2-GFP) and mitochondrial SBP2 isoforms (mtSBP2-GFP) in C33A cells was visualized by ﬂuorescence microscopy. Mitochondria
were stained with MitoTracker Red CMX-Ros. Single Z-layer deconvolution images show strong mitochondrial localization of mtSBP2-GFP
(yellow) but not of FLSBP2-GFP. (B) Western blot of SBP2 isoforms expressed from cDNAs as GFP-fusion proteins. SBP2_2-GFP and
SBP2_3a-GFP lack exons 2 and 3a respectively. mtSBP2-GFP cDNA begins at the ATG in exon 2. These proteins were resolved on a 6%
SDS–PAGE gel, which yielded a higher level of separation compared to Figure 3. (C) High resolution single Z-layer deconvolution images show the
localization of mtSBP2-GFP and endogenous mtSBP2 proteins at the mitochondria in C33A cells. 10% of cells display strong mitochondrial staining
as shown by the yellow staining in the top panel enlargement, while in most cells only a few dots were detected within the mitochondria (middle
panel). Immunoﬂuorescence staining was performed with the anti-SBP2 antibody EC1. Enlargements show a similar punctated staining pattern along
the mitochondria for both mtSBP2-GFP (bottom panel) and endogenous mtSBP2.
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ﬂuorescence observed. Notably, mtSBP2-GFP was poorly
expressed in comparison to other isoforms and we consis-
tently observed this in several cell lines tested. It is also
interesting to note that cells transfected with a construct
that lacks exon 2 (SBP2_2-GFP) expressed high levels of
proteins initiating in exons 3a, 3b and 5 (Figure 4B, lane
4), while lack of exon 3a (SBP2_3a-GFP) did not seem
to have a similar eﬀect on proteins initiating in exons 3b
and 5 (Figure 4B, lane 3). These results suggest that exon 2
might play a role in regulating the expression of some of
the SBP2 isoforms by suppressing translation initiation at
ATG start sites in exons 3a, 3b and 5. These results are
also in agreement with the results from the minigene assay
where mutation to the exon 2 ATG start site led to
increased translation from exon 3b.
We also sought to determine whether the mtSBP2 iso-
form, or additional spliced variants could be detected
endogenously in cells using our previously described
anti-SBP2 antibody raised against an epitope in exons
6–8 (aa 279–378 in SBP2) (14) which should detect most
isoforms, if expressed. However, we were unable to detect
any SBP2 isoforms other than the full-length SBP2 by
western blotting. Similarly, analysis of mitochondrial frac-
tions of cells failed to reveal the existence of mtSBP2 by
western blotting and this antibody was not suitable for
immunoﬂuorescence-based detection of mtSBP2 due to
similar level of staining in SBP2-depleted and normal
cells. Notably, a new anti-peptide antibody raised against
the C-terminus of SBP2 (referred to as anti-SBP2 EC1)
was shown to be very speciﬁc for SBP2 (data not
shown). We used this antibody in immunoﬂuorescence
of C33A cells and found that the majority of cells
showed a distinct punctated cytoplasmic staining
(Figure 4C, middle panel). Interestingly, while most cells
also showed some punctated staining along the mitocho-
dria, 5–10% of cells displayed a clear mitochondrial
SBP2 staining that co-localized strongly with
MitoTracker in (Figure 4C, top panel and enlargement).
This staining pattern was similar to that observed for
overexpressed mtSBP2-GFP (Figure 4C, bottom panel
and enlargement). Collectively, these results provide evi-
dence that mtSBP2 contains a functional MTS that targets
the mtSBP2-GFP protein to the mitochondria, and also
that endogenous mtSBP2 localizes to the mitochondria.
Although the EC1 antibody did detect full-length SBP2
by western blotting, we were unable to conﬁrm the pres-
ence of mtSBP2 isoform in mitochondrial fractions of cells
by this method.
Coordinated transcriptional and translational regulation of
SBP2 following UVA treatment
We previously showed that SBP2 is regulated through
redox-state and localization changes, and that these
aﬀect selenoprotein synthesis (14). In this study, we
wished to investigate if oxidative stress may cause tran-
scriptional changes in SECISBP2 expression, particularly
in the full-length and mitochondrial transcripts. To com-
plement our previous data, we used UVA irradiation, a
physiologically relevant oxidative stress inducer that
causes intracellular damage by production of oxygen
singlet (O2
) molecules. To monitor the transcriptional
response of SBP2, HeLa cells were exposed to 50 kJ/m2
UVA irradiation and allowed to recover for the indicated
amounts of time, and SECISBP2 and mtSECISBP2
transcript levels were measured by real-time RT-PCR.
Interestingly, we found that both transcripts were induced
by almost 3-fold immediately after UVA treatment, fol-
lowed by a sharp decline at 2 h and subsequent stabiliza-
tion of both transcripts for up to 24 h (Figure 5A).
Importantly, these results show that both transcripts are
regulated in a similar manner in response to oxidative
stress. The response to UVA treatment at the protein
level correlates well with the transcriptional response.
We observed a rapid degradation of SBP2 with levels
down to 30% of mock-treated cells at 0 h after treatment
(Figure 5B). Interestingly and as reported previously (33),
the stress sensor HSP70 protein was stabilized in response
to UVA treatment and remained elevated for 16 h post
treatment (Figure 5B). We believe that the rapid degrada-
tion of SBP2 during the course of UVA irradiation is the
trigger for the concomitant transcriptional induction seen
in Figure 5A. Although, SBP2 protein levels recovered
slightly at 2 h post treatment, they remained at only
50% of the initial levels for up to 8 h and returned to
the initial starting levels by 24 h post treatment. These
results are consistent with our previous observations that
selenoprotein synthesis is inhibited in response to oxida-
tive stress and suggest that down regulation of SBP2 pro-
tein levels might provide additional mechanistic
explanation for those observations (6,14).
We also investigated the UVA stress response pattern of
the SBP2 isoforms expressed by the minigene constructs.
We conducted a similar time course experiment in
response to UVA treatment in HeLa cells expressing
wild-type SBP2 protein (WT-SBP2GFP), the exon 2
ATG>CTG mutated SBP2 (ATGm-SBP2GFP) and the
SBP2 mutated protein that initiates translation from
exon 3b (E3b-SBP2GFP). As shown in Figure 5C, all
minigene products showed a similar down-regulation pat-
tern in response to stress, as seen for endogenous SBP2.
Similar results were obtained in NFF cells (data not
shown). From these experiments we thus conclude that
mutation of the ATG codon in exon 2 and thus the
lack of mtSBP2 expression does not aﬀect the response
of the full-length SBP2 to UVA-induced oxidative
stress, and that the spliced variants E3b-SBP2GFP and
E5-SBP2GFP (data not shown) have a similar pattern of
regulation as full-length SBP2 in response to stress.
Importantly, these experiments established a coordinated
transcriptional and translational mechanism of SBP2 reg-
ulation in response to oxidative stress, and revealed that
the alternatively spliced transcripts and the corresponding
proteins have a similar pattern of regulation as the full-
length SBP2.
DISCUSSION
SBP2 is a critical factor for selenoprotein synthesis, with
roles in SECIS element binding, ribosome binding and Sec
incorporation. Much of recent work has elaborated on
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understanding its role in the translation of 25 mammalian
selenoproteins, by detailed molecular and biochemical
characterization. Mutations in the SECISBP2 gene that
either alter the reading frame through splicing defects or
alter the interaction of SBP2 with a subset of SECIS ele-
ments due to amino acid substitutions, result in abnormal
thyroid hormone function in humans (15,25). In this
study, we presented the ﬁrst detailed in vivo and in silico
characterization of human SECISBP2 alternative splicing
and highlighted a new mode of transcriptional and trans-
lational regulation. Interestingly and intriguingly, the
most abundant SBP2 variant after the full-length SBP2
contains a MTS, which we showed is functional and
required for targeting of the mtSBP2 protein to mitochon-
dria. A small proportion of the endogenous SBP2 pool is
also localized to the mitochondria, however, only a small
fraction of cells appeared to have strong mitochondrial
SBP2 localization. This suggests that the mitochondrial
localization of SBP2 may be tightly regulated and may
occur predominantly during certain, yet unidentiﬁed
conditions.
The identiﬁcation of a potential mitochondrial human-
speciﬁc SBP2 isoform was an intriguing and somewhat
puzzling ﬁnding when viewed against the known SBP2
function in decoding UGA as Sec during selenoprotein
translation. This process is unlikely to occur within the
inner mitochondria for the following reasons: (i) analysis
of the mitochondrial genome using the SECISearch pro-
gram (34) suggests that the human mitochondrial genome
does not contain any genes with SECIS elements and
hence does not encode selenoproteins; (ii) UGA codes
for tryptophan in the human mitochondrial genome; and
(iii) mitochondrial matrix translation uses a mechanism
similar to that of prokaryotes. These facts would argue
against the requirement of a mitochondrial SBP2 isoform
with canonical function in Sec incorporation. However,
emerging evidence suggests that translationally active
cytoplasmic ribosomes, or polysomes, are present on the
outer membrane of the mitochondria and that about 50%
of mRNAs coding for mitochondria-localized products
are primarily associated with mitochondria-bound poly-
somes (35–37). Targeting mRNAs to the mitochondria is
mediated by conserved secondary structures in their 30
UTR (36). Although this process is poorly understood,
it is possible that the conservation of localized translation
might assist in the co-translational import of hydrophobic
proteins into mitochondria to prevent their aggregation in
the cytoplasm, or to simply provide a more eﬃcient way of
translation, as one mRNA molecule can serve in several
rounds of translation. The mitochondrial SBP2 isoform
could thus function in the translation of selenoproteins
targeted to mitochondria such as thioredoxin reductase 2
(TxnRd2/TR3) (1,38), mitochondrial form of phospholi-
pid glutathione peroxidase (PHGPx/GPx4) (39) and glu-
tathione peroxidase 1 (GPx1) (40) on mitochondria-bound
cytoplasmic ribosomes. Alternatively, mtSBP2 could be
involved in binding to mRNA structures, possibly also
in non-selenoprotein encoding mRNAs that target the
message to the outer mitochondrial ribosomes. The
high-resolution images we obtained of both over-
expressed mtSBP2-GFP and endogenous mtSBP2 pointed
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Figure 5. Coordinated transcriptional and translational regulation of
SBP2 following UVA treatment. Transcriptional and translational
response of full-length SBP2 (FLBSP2) and mitochondrial SBP2
(mtSBP2) following 50 kJ/m2 of UVA irradiation was monitored in
HeLa cells over 24 h. (A) Real-time RT-PCR using transcript speciﬁc
primers shows a similar transcriptional induction of both transcripts in
response to treatment. (B) Western blot using anti-SBP2 antibodies
shows the translational response of endogenous SBP2 and HSP70 at
diﬀerent time points after UVA irradiation. Quantitation of FLSBP2
transcript and protein levels is presented in the graph below. Error bars
represent the standard error of the mean (SEM). Transcript levels were
normalized against GAPDH and protein levels were normalized against
actin. (C) Western blots show the translational response of WT,
Ex2ATG>CTG and Ex3AG>AA minigene-derived proteins to UVA
treatment. HSP70 was used as a marker for UVA-induced stress and
actin shows protein loading.
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to a localization of the mtSBP2 isoform on the outer mito-
chondrial surface, in speciﬁc punctate clusters. This loca-
lization would indeed be in agreement with the functional
localization of SBP2 at polysomes. The fact that we could
not detect mtSBP2 in mitochondrial subfractions of cells
by western blotting argues for a possible loose interaction
between mtSBP2 and the organelle, which may be easily
disrupted during the fractionation procedure. But if
mtSBP2 is localized on the outer surface of the mitochon-
dria, why would it require a classical type of MTS that
generally targets proteins to the inner mitochondrial
matrix? Although this question remains to be answered,
our ﬁndings are relevant to a recent report showing that
DAKAP1, a multifunctional protein with roles in cAMP
dependent protein kinase (PKA) regulation and mRNA
binding, can be targeted to the cytosolic side of the
outer membrane of the mitochondria by use of a classical
MTS. DAKAP1 contains a bi-functional targeting motif
that switches to encode either an MTS, such as the one
present in mtSBP2, or an ER targeting signal (41).
Although the precise mechanism of how this protein
attaches to the mitochondria outer membrane remains
unknown at present, it is possible to reconcile the idea
that proteins that localize on the cytosolic side of the
mitochondrial membrane can be targeted there by classi-
cal MTSs. The MTS in mtSBP2 may thus facilitate the
localization of the protein to the cytosolic side of the
mitochondria via active mitochondrial import. More
detailed studies will be required to investigate this
aspect of mtSBP2 localization as well as the precise role
of this isoform in the cell. The low expression of mtSBP2
isoform in the cell lines tested indicates that its syn-
thesis could be dependent on tissue-speciﬁc translation
factors and may be maximized in tissues or organs with
high demand for mitochondrial selenoproteins. A
prime candidate would be testis, where PHGPx is the
most abundant selenoprotein. Indeed, the expression of
both full-length SECISBP2 and mtSECISBP2 transcripts
was highest in testis when compared to twelve other tis-
sues, providing additional proof to strengthen this
hypothesis.
This study established that human SECISBP2 has an
extensive alternative splicing pattern in the 50-region.
Some of the splicing events provoke ORF alterations,
which lead to premature termination codons, thus pro-
moting translation from downstream ATG start codons.
Our in vivo splicing assay and treatment with ASOs
showed that at least four additional ATG start codons
in exons 2, 3a, 3b and 5 are used to produce proteins
with diﬀerent N-terminal amino acid sequence such as
mtSBP2, or N-terminally truncated SBP2 isoforms.
Because all alternative splicing events within SBP2 are
conﬁned within the region dispensable for Sec incorpora-
tion in vitro, it is reasonable to postulate that these
events are unlikely to aﬀect RNA binding per se, however,
this level of regulation may play a ﬁne-tuning or regula-
tory role in SBP2-dependent Sec incorporation function
in vivo. The role of the N-terminal region of SBP2 is a
puzzling, yet unanswered, question in the ﬁeld. So far,
the only characterized motif within this region is a nuclear
localization signal (NLS) that enables SBP2 to shuttle
between the nucleus and cytoplasm (14), however, its
requirement for selenoprotein synthesis in vivo has not
been determined. Interestingly, the NLS is located within
exon 8, which is common to all alternatively spliced SBP2
isoforms suggesting that this motif may indeed play an
important role in the function of SBP2 in the nucleus
in vivo. Consistent with this, recent studies have suggested
a new role of SBP2 in protection of selenoprotein encod-
ing mRNAs from nonsense mediated decay by binding to
these mRNAs in the nucleus (42,43).
The human selenoproteome consists of 25 selenopro-
teins (44) but the SECIS core element and the binding
site for SBP2 are well conserved. As a result, Sec incor-
poration with regard to SECIS element binding would not
require variability within the SBP2 RNA binding region
which could explain the lack of alternate splicing in the
C-terminal region of SBP2. In contrast, the hierarchy of
selenoprotein synthesis is expected to involve speciﬁc fac-
tors that may dictate the diﬀerential binding of SBP2 to
diﬀerent selenoprotein mRNAs (25,43). The high sequence
variability in the N-terminal region of SBP2 could thus
serve as a protein–protein interaction domain and func-
tion in the recruitment of such factors prior to interaction
with the SECIS element.
In a previous study we showed that acute oxidative
stress caused by H2O2 and sodium selenite had an inhibi-
tory eﬀect on selenoprotein synthesis, and that this was
mediated by oxidation of SBP2 redox-sensitive cysteine
residues and its depletion from the ribosomes (14). In
the current study, using UVA-irradiation as a cause of
oxidative stress we found that SBP2 responded by
coordinated transcriptional and translational changes fol-
lowing stress. Importantly, SECISBP2 and mtSECISBP2
transcripts were simultaneously and immediately induced
during treatment, and stabilized during the recovery
phase. At the protein level, SBP2 was degraded and
levels remained approximately half of the initial levels
for 16 h post-irradiation. The SBP2 isoforms that we
could monitor using the minigene showed similar down-
regulation as full-length SBP2, suggesting that their intra-
cellular function is most likely related to the function
of full-length SBP2 in SECIS binding and Sec incorpora-
tion. However, our data does not exclude the possibility
that mtSBP2 or any other SBP2 isoforms may perform
additional functions unrelated to selenium metabolism.
This is the ﬁrst report validating the occurrence and
signiﬁcance of alternative splicing associated with
SECISBP2, an essential gene linked to selenium metabo-
lism. Although, we have focussed mainly on one spliced
variant, mtSECISBP2, there remain other variants of sig-
niﬁcant interest. Having shown that an ASO-based
approach could be used to generate speciﬁc spliced var-
iants, future studies could be tailored to examine their
functions. Recent years have seen a dramatic evolution
in our understating of translational regulation by
microRNAs, a class of small RNA that could be synthe-
sized by a stem-loop containing transcript generated from
RNA Polymerase II (45). To a broader signiﬁcance, it
remains to be seen if some of the poorly translatable
SECISBP2 spliced variants including mtSBP2 are meant
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to generate microRNAs and/or serve as potential targets
of microRNAs.
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